These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 27540138)
1. Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bortezomib and dexamethasone. López-Iglesias AA; González-Méndez L; San-Segundo L; Herrero AB; Hernández-García S; Martín-Sánchez M; Gutiérrez NC; Paíno T; Avilés P; Mateos MV; San-Miguel JF; Garayoa M; Ocio EM Haematologica; 2017 Jan; 102(1):168-175. PubMed ID: 27540138 [TBL] [Abstract][Full Text] [Related]
2. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells. Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312 [TBL] [Abstract][Full Text] [Related]
3. Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells. Das DS; Das A; Ray A; Song Y; Samur MK; Munshi NC; Chauhan D; Anderson KC Clin Cancer Res; 2017 Aug; 23(15):4280-4289. PubMed ID: 28270494 [No Abstract] [Full Text] [Related]
4. The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells. Chen G; Xu Z; Chang G; Hou J; Hu L; Zhang Y; Yu D; Li B; Chang S; Xie Y; Zhang Y; Wei R; Wu H; Xiao W; Sun X; Tao Y; Gao L; Dai B; Shi J; Zhu W Oncol Rep; 2017 Jul; 38(1):488-496. PubMed ID: 28560392 [TBL] [Abstract][Full Text] [Related]
5. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. San-Miguel JF; Hungria VT; Yoon SS; Beksac M; Dimopoulos MA; Elghandour A; Jedrzejczak WW; Günther A; Nakorn TN; Siritanaratkul N; Corradini P; Chuncharunee S; Lee JJ; Schlossman RL; Shelekhova T; Yong K; Tan D; Numbenjapon T; Cavenagh JD; Hou J; LeBlanc R; Nahi H; Qiu L; Salwender H; Pulini S; Moreau P; Warzocha K; White D; Bladé J; Chen W; de la Rubia J; Gimsing P; Lonial S; Kaufman JL; Ocio EM; Veskovski L; Sohn SK; Wang MC; Lee JH; Einsele H; Sopala M; Corrado C; Bengoudifa BR; Binlich F; Richardson PG Lancet Oncol; 2014 Oct; 15(11):1195-206. PubMed ID: 25242045 [TBL] [Abstract][Full Text] [Related]
6. Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair. López-Iglesias AA; Herrero AB; Chesi M; San-Segundo L; González-Méndez L; Hernández-García S; Misiewicz-Krzeminska I; Quwaider D; Martín-Sánchez M; Primo D; Paíno T; Bergsagel PL; Mehrling T; González-Díaz M; San-Miguel JF; Mateos MV; Gutiérrez NC; Garayoa M; Ocio EM J Hematol Oncol; 2017 Jun; 10(1):127. PubMed ID: 28633670 [TBL] [Abstract][Full Text] [Related]
7. Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib. Nijhof IS; Groen RW; Noort WA; van Kessel B; de Jong-Korlaar R; Bakker J; van Bueren JJ; Parren PW; Lokhorst HM; van de Donk NW; Martens AC; Mutis T Clin Cancer Res; 2015 Jun; 21(12):2802-10. PubMed ID: 25398450 [TBL] [Abstract][Full Text] [Related]
9. The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in Díaz T; Rodríguez V; Lozano E; Mena MP; Calderón M; Rosiñol L; Martínez A; Tovar N; Pérez-Galán P; Bladé J; Roué G; de Larrea CF Haematologica; 2017 Oct; 102(10):1776-1784. PubMed ID: 28751557 [TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells. Chauhan D; Ray A; Viktorsson K; Spira J; Paba-Prada C; Munshi N; Richardson P; Lewensohn R; Anderson KC Clin Cancer Res; 2013 Jun; 19(11):3019-31. PubMed ID: 23584492 [TBL] [Abstract][Full Text] [Related]
11. Zalypsis: a novel marine-derived compound with potent antimyeloma activity that reveals high sensitivity of malignant plasma cells to DNA double-strand breaks. Ocio EM; Maiso P; Chen X; Garayoa M; Alvarez-Fernández S; San-Segundo L; Vilanova D; López-Corral L; Montero JC; Hernández-Iglesias T; de Alava E; Galmarini C; Avilés P; Cuevas C; San-Miguel JF; Pandiella A Blood; 2009 Apr; 113(16):3781-91. PubMed ID: 19020308 [TBL] [Abstract][Full Text] [Related]
12. Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts. Du HF; Yu LJ; Meng YF; Lv HY; Meng J; Song XN; Zhang JQ Leuk Lymphoma; 2013 Mar; 54(3):607-18. PubMed ID: 22889356 [TBL] [Abstract][Full Text] [Related]
13. Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human multiple myeloma cells. Yang M; Huang J; Pan HZ; Jin J Int J Mol Med; 2008 Oct; 22(4):489-96. PubMed ID: 18813856 [TBL] [Abstract][Full Text] [Related]
14. DANFIN functions as an inhibitor of transcription factor NF-κB and potentiates the antitumor effect of bortezomib in multiple myeloma. Uematsu A; Kido K; Manabe E; Takeda H; Takahashi H; Hayashi M; Imai Y; Sawasaki T Biochem Biophys Res Commun; 2018 Jan; 495(3):2289-2295. PubMed ID: 29284118 [TBL] [Abstract][Full Text] [Related]
15. The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care. Paíno T; Garcia-Gomez A; González-Méndez L; San-Segundo L; Hernández-García S; López-Iglesias AA; Algarín EM; Martín-Sánchez M; Corbacho D; Ortiz-de-Solorzano C; Corchete LA; Gutiérrez NC; Maetos MV; Garayoa M; Ocio EM Clin Cancer Res; 2017 Jan; 23(1):225-238. PubMed ID: 27440267 [TBL] [Abstract][Full Text] [Related]
16. A novel phosphoramide compound, DCZ0847, displays in vitro and in vivo anti-myeloma activity, alone or in combination with bortezomib. Chen G; Hu K; Sun H; Zhou J; Song D; Xu Z; Gao L; Lu Y; Cheng Y; Feng Q; Zhang H; Wang Y; Hu L; Lu K; Wu X; Li B; Zhu W; Shi J Cancer Lett; 2020 May; 478():45-55. PubMed ID: 32160976 [TBL] [Abstract][Full Text] [Related]
17. Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma. Siegel MB; Liu SQ; Davare MA; Spurgeon SE; Loriaux MM; Druker BJ; Scott EC; Tyner JW Oncotarget; 2015 Aug; 6(22):18921-32. PubMed ID: 26254279 [TBL] [Abstract][Full Text] [Related]
18. CDK5 inhibition in vitro and in vivo induces cell death in myeloma and overcomes the obstacle of bortezomib resistance. Tang H; Xu L; Cen X; Yang L; Feng J; Li G; Zhu H; Gao S; Yu Y; Zhao Y; Tian Z; Hou L; Yu S; Gao G Int J Mol Med; 2020 Jun; 45(6):1661-1672. PubMed ID: 32236619 [TBL] [Abstract][Full Text] [Related]
19. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364 [TBL] [Abstract][Full Text] [Related]
20. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib. Malek E; Driscoll JJ Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]